Personalized therapy does not reduce hospitalization in chronic kidney disease
1. In this randomized controlled trial, algorithmic identification based on electronic health...
Read MoreJun 3, 2024
1. In this randomized controlled trial, algorithmic identification based on electronic health...
Read MoreMay 27, 2024
1. Post-traumatic stress disorder (PTSD) symptoms were associated with higher levels of chronic...
Read MoreMay 24, 2024
1. In this randomized controlled trial, lixisenatide reduced motor disability progression in...
Read MoreMay 24, 2024
1. For diabetic patients undergoing hemodialysis, receiving foot and ankle care from a podiatrist...
Read MoreMay 24, 2024
1. In this retrospective study, the chest X-ray cardiovascular disease (CXR CVD)-risk model...
Read MoreMay 24, 2024
1. In patients undergoing peritoneal dialysis, osteoporosis is highly prevalent but does not...
Read MoreMay 23, 2024
1. In this dose-escalation study, using intrathecal gene transfer with scAAV9/JeT-GAN demonstrated...
Read MoreMay 22, 2024
1. Target-vessel failure was significantly lower in the ultrasound-guided group than the...
Read MoreMay 21, 2024
1. The 18-month event-free survival in the perioperative nivolumab group was 70.2% vs 50.0% in the...
Read MoreMay 21, 2024
1. In this observational study, inpatients treated by a female physician had lower 30-day...
Read MoreMay 21, 2024
1. A decision support system using the Molecular International Prognostic Scoring System (IPSS-M)...
Read MoreMay 18, 2024
1. Consumption of ultra-processed foods was associated with modestly higher all cause mortality,...
Read MoreMay 17, 2024
1. At 12 months, patients with anterior cruciate ligament reconstruction randomized to receive...
Read MoreMay 15, 2024
1. 3-year invasive disease-free survival among the PET-based treatment group was 94.8%. 2. There...
Read MoreMay 15, 2024
1. Among patients on anticancer treatment with malignancy who were 75 years of age or older, the...
Read MoreMay 14, 2024
1. Although capecitabine or XELOX did not improve overall survival when compared to PF, efficacy...
Read MoreMay 14, 2024
1. The objective response rate for trastuzumab deruxtecan was 29.4%. 2. Treatment-emergent adverse...
Read MoreMay 14, 2024
1. Achieving Minimal Residual Disease (MRD) negativity at baseline before lenalidomide...
Read MoreMay 14, 2024
1. The use of recombinant L-IFN adenovirus in patients with recurrent or refractory advanced solid...
Read MoreMay 13, 2024
1. Increased incidence of radiographic knee osteoarthritis was associated with high amounts of...
Read More